Santhera Pharmaceuticals’ Post

Clinigen Insights 2024 – We are live! Managed Access: From concepts to action - discussing practical insights, case studies and more around this topic at our Clinigen Insights conference in Barcelona this week. Kieron Lewis Elizabeth Taylor Pete Solman Claudia Martínez #managedaccess #expandedaccess #earlyaccess #realworlddata #clinigeninsights

Exciting News! Today, I have the privilege of giving a webinar on the 'Secondary Use of Health-Related Data' for the members of Healixia. I'm thrilled to be sharing the virtual stage with Zenzi De Graeve (DPO of Galapagos). We'll be exploring the intricacies of secondary use of data in healthcare, providing insights, and discussing potential opportunities. Looking forward to a productive session. #HealthcareData #Webinar #SimmonsAndSimmons #Galapagos #Healixia

Landmark RCT - pronounces further, the clinical relevance of intermediate sizes on Effective Orifice Area.

🚀 Exciting News! 🚀 I’ll be pitching at the 2nd Biotech Summit Austria in Innsbruck on October 10th! Join us from October 10-11, 2024, as syndena showcases our cutting-edge solution for healthcare data management. During my presentation, I’ll be diving into how syndena insights is transforming the way we approach healthcare data by bridging the gap between primary and secondary use. This is a fantastic opportunity to discuss the future of data in life sciences and how we’re driving change in the industry. If you're attending, I’d love to connect and chat about how we can shape the future of real world evidence together! Looking forward to seeing you there! 🙌 #BiotechSummit #LifeSciences #HealthcareInnovation #DataScience #syndena #HealthcareTransformation

As we anticipate the #LNIF24, let’s remind ourselves the true spirit of the forum by drawing inspiration from the remarkable journey of David Fajgenbaum, MD, MBA, MSc., co-founder of Every Cure, who personifies the essence of #collaboration in #healthcare.   David's story is rooted in repurposing a drug to cure a #raredisease, a narrative that now forms the core of Every Cure, which has repurposed 17 FDA-approved drugs to date.   Together with Tania Simoncelli, Vice President of Science in Society at the Chan Zuckerberg Initiative (CZI), and others, they were able to build collaborative research networks for rare disease communities and more.   The Lake Nona Impact Forum, serving as a dynamic hub for innovations and collaborations, has been instrumental in propelling David's healthcare mission forward. According to Gloria Caulfield, VP of Strategic Alliances at Tavistock Development Company and President of Lake Nona Institute, David's work epitomizes the true spirit of the Impact Forum.   #AdversityToImpact https://lnkd.in/eNnwiz9

Explore #Navitian's crossing capacity in the #ClinicalCase by Dr Ignacio J Amat Santos and find out why is key to success in an antegrade approach ➡️ https://lnkd.in/dCcfMPP3 #iVascular #ClinicalCases

What do you identify as your most significant personal challenge ahead of 2025? This was one of the questions we discussed as organizers and participants were preparing for some of the upcoming iVentiv meetings. Among others, we talked about economic trends, technological advancements, and workforce changes that impact various business operations. Thank you for the great discussions, Charles Jennings, Claudia Pugliese, Davelene Marshall, Gregor Herr, Hannah Hoey, Jay Moore, Jose Pablo Vera Fernandez, Julija Lavrac Dr., Kristy Kitson, Melissa Milani, Priya Thaman, Robin LeBlanc, Satoshi Probala, Sandy R., Sina Melder, Titusz Kovacs. I look forward to the upcoming iVentiv meeting in October, on the Novartis campus, in Basel. My most significant personal challenge is continuously becoming the person I want to be. Curiosity is certainly a good start. What is it for you? 👇 Please share below. #challenge #landd #learninganddevelopment #lifelonglearning #economy #technology #workforce #business #curiosity

Last week, I had the pleasure to visit the lively community of scientists involved in the #HorizonEU project “Providing cutting edge cancer research services across Europe”. canSERV Led by the Research Infrastructure BBMRI-ERIC, canSERV is a unique #ResearchInfrastructures project providing to EU researchers the chance to use borderless more than 400 front-edge instruments and services. The final goal is to unchain #CancerResearch in Europe by democratising the access to the latest technologies available in EU. Selected scientists can travel and use the facilities with no costs. This is a key aspect of the Horizon Research Infrastructure programme for TransNational Access (TNA) offered by #INFRASERV projects. In canSERV, 18 partners, including 13 EU Life sciences Research Infrastructures, and their scientists are helping EU researchers and small medium enterprises (SME) to answer most prominent questions on personalised oncology, understanding the mechanisms of cancer, patient care, develop clinic applications from research and training the next generation of cancer researchers.  All aspects of oncology research are covered from provision of disease models, personalised oncology, biomarker research, digital and translational medicines services, access to samples as well as support for organisation of clinical trials or ethics and legal issues.  The project is still ongoing, researchers have the great opportunity to apply to the next open calls and to get the chance to turn ideas into scientific evidence. If so, stay connected 👉 https://lnkd.in/eMF8c9xu canSERV fits well with the aim of the #EUCancerMission and with Europe’s beating Cancer plan to support initiatives for a wide impact on citezens and their health for prevention, early detection, diagnosis and treatment and quality of life of patients and survivors.

New interviews about the positive results from Alzinova AB's phase 1b study with the vaccine candidate AL1-101 against Alzheimer's Disease. Check out the interviews by Redeye AB and Alzheimerfonden (in Swedish) - link below. #alzheimers #clinicaltrials #vaccine

Check out my recent pitch at the MedInvest conference in San Francisco. We are making great progress. We have filled about half of our Series B. We would like to welcome additional investors. #Newronika #Brainmodulation #Parkinsons #Neuromodulation #DBS #adaptiveDBS #aDBS #venturecapital #alphaDBS